The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.
about
Cancer Hallmarks, Biomarkers and Breast Cancer Molecular SubtypesUse of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineMVDA: a multi-view genomic data integration methodology.TIMP-1 and responsiveness to gemcitabine in advanced breast cancer; results from a randomized phase III trial from the Danish breast cancer cooperative group.Alteration of topoisomerase II-alpha gene in human breast cancer: association with responsiveness to anthracycline-based chemotherapy.Osteoprotegerin secreted by inflammatory and invasive breast cancer cells induces aneuploidy, cell proliferation and angiogenesis.Oncogene amplification in male breast cancer: analysis by multiplex ligation-dependent probe amplificationPrognostic significance of TOP2A gene dosage in HER-2-negative breast cancerInterlinked DNA nano-circles for measuring topoisomerase II activity at the level of single decatenation events.Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.Topoisomerase II alpha gene copy loss has adverse prognostic significance in ERBB2-amplified breast cancer: a retrospective study of paraffin-embedded tumor specimens and medical charts.CEF is superior to CMF for tumours with TOP2A aberrations: a Subpopulation Treatment Effect Pattern Plot (STEPP) analysis on Danish Breast Cancer Cooperative Group Study 89D.Are we approaching the post-blockbuster era? Pharmacodiagnostics and rational drug development.Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A statusAmplification of HER2 and TOP2A and deletion of TOP2A genes in a series of Taiwanese breast cancer.Somatic alterations of targetable oncogenes are frequently observed in BRCA1/2 mutation negative male breast cancers.Useful genetic variation databases for oncologists investigating the genetic basis of variable treatment response and survival in cancer.Integrated diagnostic network construction reveals a 4-gene panel and 5 cancer hallmarks driving breast cancer heterogeneity.Aberrations of ERBB2 and TOP2A genes in breast cancer.Failure pattern and survival after breast conserving therapy. Long-term results of the Danish Breast Cancer Group (DBCG) 89 TM cohort.Clinicopathological Significance of the Proliferation Markers Ki67, RacGAP1, and Topoisomerase 2 Alpha in Breast Cancer.Lack of independent prognostic and predictive value of centromere 17 copy number changes in breast cancer patients with known HER2 and TOP2A status.Exploratory study on the correlation between 14 lung cancer-related gene expression and specific clinical characteristics of NSCLC patients.Role of Topoisomerases in Pediatric High Grade Osteosarcomas: TOP2A Gene Is One of the Unique Molecular Biomarkers of Chemoresponse.Validity of the proliferation markers Ki67, TOP2A, and RacGAP1 in molecular subgroups of breast cancer.Topo2A as a prognostic biomarker for patients with resectable esophageal squamous cell carcinomas.Dual-colour CISH is a reliable alternative to FISH for assessment of topoisomerase 2-alpha amplification in breast carcinomas.DBCG: the Danish Breast Cancer Cooperative Group--a 30-year struggle for better breast cancer treatment in Denmark.Over-expression of EPS15 is a favorable prognostic factor in breast cancer.Prognostic value of TOP2A gene amplification and chromosome 17 polysomy in early breast cancer.Prognostic and predictive value of copy number alterations in invasive breast cancer as determined by multiplex ligation-dependent probe amplification.Overexpression of topoisomerase II alpha protein is a factor for poor prognosis in patients with luminal B breast cancer.Copy number variation and high expression of DNA topoisomerase II alpha predict worse prognosis of cancer: a meta-analysis.
P2860
Q26743510-E291A0B9-A3E0-41F6-86BD-542712B53658Q28079118-4CA9D461-24A5-4644-BF6E-BA0EBA2B0E83Q30987838-2D85392D-8BE4-4270-98C8-AC5332E9082CQ33880656-F80BA874-DCD9-42C8-9A0E-0690B286847AQ34743488-C835560D-CC24-437C-A8BF-CA69720D3FF6Q35853271-5E537971-2AB7-4281-85CA-004F488D9F41Q36147178-4685C0A6-3895-42B5-B3A3-E9D5761822A9Q36349584-C32832FD-A926-45C8-BAB3-9E30D4967685Q36379849-980411BE-E10E-4C13-A1CD-867C55561072Q36402262-458E876D-F653-4D1A-902A-CAEB98E54945Q36897329-243BB1E7-E364-466F-8EA6-9E42CE1EB890Q37040549-26ED7D8E-2E95-4D82-B6A3-3A934D707BBCQ37322436-C5C40F11-79B2-40AA-942E-D76830D299EDQ37324977-80151E3B-70DD-41F7-8B03-C8946CC7F878Q37606324-73CBBC1E-4D30-422B-B6FE-EDCEEAFC0A80Q37687527-E9A01BCF-F5B1-4B88-8E8A-BB979501B9E9Q37776496-85ED6790-ABFD-466C-BC76-1BED88504334Q38430594-7EEDFA1E-8DEB-4167-B349-6A81632163B3Q39769567-20300689-EB07-47E0-ADCE-0450514E9727Q39817629-174491BD-03F6-4177-A2B4-939437855ED9Q40708757-5B6FE307-A0C2-4993-83B4-3199593C2A68Q41133771-6AEED3F2-FAFF-40DF-8216-9DDFD3C47133Q41920903-5FE54EA5-DC46-4DC0-8208-89B5495722D4Q43065457-85957E45-1C57-4B94-8A1C-5DB9B4D99DB1Q43549877-09D79B7D-0EEE-49FA-BA03-B7E4157009ADQ44217410-03482D3A-5FC9-4126-83B2-04689B15F594Q44358325-119C48BA-94D1-48B5-9386-095CDBE8BD4BQ50547499-5EAB3339-08A2-4B22-AD75-82EE121A6B01Q51802525-A79F7F58-AEFB-41F9-BA2B-8C3032CAE4D6Q54318735-AE748FF9-DEA5-4094-ACAD-389830ED2A26Q54374707-01D19911-E305-41B8-B26C-28B4C29971DDQ55176796-EC4FA29B-37D8-4253-95EF-4F8E4F0ED32FQ55396428-84207302-E4B5-4FAC-8F2E-61FF101391BB
P2860
The value of TOP2A gene copy number variation as a biomarker in breast cancer: Update of DBCG trial 89D.
description
2008 nî lūn-bûn
@nan
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
2008年论文
@zh
2008年论文
@zh-cn
name
The value of TOP2A gene copy n ...... cer: Update of DBCG trial 89D.
@en
type
label
The value of TOP2A gene copy n ...... cer: Update of DBCG trial 89D.
@en
prefLabel
The value of TOP2A gene copy n ...... cer: Update of DBCG trial 89D.
@en
P2093
P2860
P1433
P1476
The value of TOP2A gene copy n ...... ncer: Update of DBCG trial 89D
@en
P2093
Bent Ejlertsen
Helle Knudsen
Henning T Mouridsen
Jan Trøst Jørgensen
Susanne Møller
P2860
P304
P356
10.1080/02841860801995396
P577
2008-01-01T00:00:00Z